AbCheck: Antibody Discovery Deal

First validation of technology and business approach

07-Oct-2010 - Czechia

AbCheck s.r.o. announced an antibody discovery deal with Eli Lilly and Company. Under the agreement, AbCheck will use its three antibody discovery libraries to deliver high-affinity, fully human antibodies against an undisclosed number of Lilly targets. The three distinct human antibody libraries comprise a total of about 10 billion sequentially and structurally diverse antibodies. Lilly, which has full rights to any antibodies selected, will pay AbCheck discovery fees and development milestone payments. Other financial and deal terms are not disclosed.

"This discovery deal with Lilly is an important validation of our antibody discovery and business approach," said Dr Volker Lang, Managing Director of AbCheck. "Signing our first deal with such a significant company so soon after setting up AbCheck, has certainly given us a tremendous boost of confidence that AbCheck is following a successful business strategy."

AbCheck's libraries are designed as universal tools for the isolation of antibodies against all possible targets. This breadth of targets differentiates the libraries from immunized libraries, which are restricted to only a minor fraction of therapeutically interesting target antigens.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous